Dec 09, 2019 / 01:30AM GMT
Jeffrey W. Albers - Blueprint Medicines Corporation - CEO, President & Director
First off, on behalf of all the employees of Blueprint Medicines, want to thank all of you for sharing a Sunday evening with all of us, and I also want to welcome those of you participating on the webcast.
As always, we'll be making forward-looking statements and refer you to our website or the SEC filing documents and fully disclaim any obligation to update those forward-looking statements.
Agenda-wise, I'll start off with some brief introductory comments, then I'm going to turn it over to Dr. Dan DeAngelo from Dana-Farber and Harvard, who were thrilled to join us tonight. He's an investigator on all 3 of the trials in systemic mastocytosis with avapritinib. Then Andy Boral will talk a little bit about our development plan and pull the data together, and then we'll close and really focus our time together for Q&A before I wrap it up for -- with closing remarks. I've been told that I have to stick strictly to one hour, so we'll try to cover all of our comments within 40, 45 minutes to leave time for
Blueprint Medicines Corp to Host Investor Event and Webcast to Review Initial Data from the PIONEER Trial Presented at ASH Transcript
Dec 09, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers